Table 2.

Treatment responses after induction therapy and completion of 1 or 2 years of lenalidomide maintenance

ResponseBest responseEnd of induction therapy (8 cycles of KRd therapy)After completion of 1 year of maintenance*After completion of 2 years of maintenance*
n/N%n/N%n/N%n/N%
ORR 18/18 100 18/18 100 18/18 100 18/18 100 
≥VGPR 18/18 100 18/18 100 18/18 100 18/18 100 
nCR 1/18 6 6/18 33 1/18 6 1/18 6 
sCR/CR 16/18 89 11/18 61 16/18 89 16/18 89 
MRD-negative CR 15/18 83 10/18 56 10/16 63 10/16 63† 
ResponseBest responseEnd of induction therapy (8 cycles of KRd therapy)After completion of 1 year of maintenance*After completion of 2 years of maintenance*
n/N%n/N%n/N%n/N%
ORR 18/18 100 18/18 100 18/18 100 18/18 100 
≥VGPR 18/18 100 18/18 100 18/18 100 18/18 100 
nCR 1/18 6 6/18 33 1/18 6 1/18 6 
sCR/CR 16/18 89 11/18 61 16/18 89 16/18 89 
MRD-negative CR 15/18 83 10/18 56 10/16 63 10/16 63† 

nCR, near complete response; n/N, number of patients achieving the response/number of patients assessed at the time point; ORR, overall response rate; sCR, stringent complete response; VGPR, very good partial response.

*

Lenalidomide maintenance: lenalidomide 10 mg once per day on days 1 to 21 on a 28-day cycle.

†

One patient refused to have a bone marrow biopsy procedure and 1 patient withdrew from therapy but was MRD negative after 6 months of maintenance therapy.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal